Patients with hormone-refractory disease and Karnofsky performance status (KPS) of ≤ 60% had median survival of 2.5 months, whereas those with KPS of 70% and KPS of ≥ 80% had a median survival of 7 months and 18 months, respectively (p < 0.001).
It is noteworthy that 69.2% of patients had KPS of 80-100, while no difference was shown in any scale or item of QLQ-C30 among these KPS subgroups (KPS 80, 90 and 100; data not shown).
Patients with hormone-refractory disease and bad performance status (KPS ≤ 60%, n = 11) had a median survival of 2.5 (0.25 5) months, whereas those with a KPS of 70% (n = 22) and a KPS of ≥ 80% (n = 8) had median survival of 7 (0.3 36) and 18 (4–27) months, respectively (p < 0.001).
In contrast, one of three (33%) patients underwent NovoTTF-100A, bevacizumab and TCCC treatment at her fourth recurrence and she had a poor KPS of 60, while the other two (67%) received treatment at their second glioblastoma recurrence and their KPS was at 70.
The emulsion formulations prepared also contained 0.5% radical initiator KPS (of total monomer on weight basis), anionic surfactant Dowfax 2A1 and sodium bicarbonate as a buffer.
In all studied parks logarithms of the gas/particle partitioning coefficients (Kps) of PCDD/F homologues were linearly correlated with those of their sub-cooled vapor pressures (pLs).
The patient was lost from follow-up and came back in 2003, after 4 years, with an anterior inflammation with granulomatous inferior KPs of the same eye, slight band keratopathy, depigmentation of the inferior iris, posterior iris synechiae, and posterior subcapsular cataract.
Karnofsky Performance Score (KPS) of at least 70 was required.
Median KPS was 80 (range 70 100); 62 patients had KPS of >70.
The median KPS of the entire patient population was 80 at the time of salvage treatment.
All patients had KPS of 70 or above upon the last follow-up.
